Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn to $34bn on Tuesday, as higher prices offset a slowdown in demand outside the US.
The US drugmaker said strong sales of its bivalent booster, which targets the Omicron variant’s dominant strain, and some of its other drugs helped it offset damage from a strong dollar.
The company maintained its full-year forecast of $22bn for sales of its Covid antiviral pill Paxlovid, as it posted third-quarter results that beat analysts’ expectations and soothed concerns around weaker demand for Covid products.
您已閱讀17%（565字），剩余83%（2677字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。